Connect Biopharma Reports Significant Loss Amid Development Efforts
I'm PortAI, I can summarize articles.
Connect Biopharma Holdings Ltd. reported a significant net loss of $17.2 million for Q3 2025, with a total net loss of $40.4 million for the first nine months of 2025. The company's cash reserves decreased from $78.2 million at the end of 2024 to $37.8 million by September 30, 2025. Despite financial challenges, the company continues its clinical trials and collaborations, including a partnership with Simcere Pharmaceutical for rademikibart in Greater China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments